Our technologies facilitate high throughput, precise analyte quantitation and multiplexing. One day our approach will make random access to broad test panels created on-demand on instrument systems placed across the bioanalytical application space a reality.
For instance, on the spot doctors will be able to select tests from a broad menu and combine them into panels of interest in the respective clinical context. Our research products are designed to provide smooth transfer of developed laboratory assays onto a cutting-edge point-of-care platform.
BLINK is founded on robust intellectual property (IP) encompassing nanoreactor beads, advanced processing tools for these beads, and assays utilizing nanoreactor beads. Our business model centers around the licensing of our IP to commercial partners with a strong market presence and the capability to manufacture, distribute, and support products derived from nanoreactor bead technology.
Developers can create complete products for research or diagnostics by combining their analyte specific reagents with the generic modules of the BLINK technology package. Of course, individual modules can also be integrated into existing workflows or lab automation solutions.